1.
Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.
by Miller, Michael D
The Journal of infectious diseases, March 1, 2004, Vol.189(5), pp.837-846

2.
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a random...
by Sax, Paul E
The Lancet, 30 June 2012, Vol.379(9835), pp.2439-2448

3.
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised,...
by Sax, Paul E
The Lancet, 27 June 2015, Vol.385(9987), pp.2606-2615

4.
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomi...
by Molina, Jean-Michel
The Lancet Infectious Diseases, Jan 2012, pp.27-35

5.
A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults
by Huhn, D., Gregory
JAIDS Journal of Acquired Immune Deficiency Syndromes, 2017, Vol.74(2), pp.193-200

6.
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabin...
by Wohl, David
Journal of Acquired Immune Deficiency Syndromes, May 1, 2016, p.58
